autoimmune mechanisms and treatment approaches in graves' disease-induced hyperthyroidism: a comprehensive review

Graves' disease represents the predominant etiology of hyperthyroidism globally, affecting 60-80% of hyperthyroid cases worldwide. this autoimmune disorder results from thyroid-stimulating immunoglobulins (tsi) inappropriately activating thyroid-stimulating hormone receptors (tshr), leading to excessive thyroid hormone production and subsequent metabolic dysfunction. the disease predominantly affects women of reproductive age, with a female-to-male ratio of 5-10:1, and exhibits significant geographical variation in prevalence and clinical presentation. this comprehensive review aims to provide an in-depth analysis of the complex autoimmune mechanisms underlying graves' disease pathogenesis and critically evaluate current therapeutic modalities alongside emerging treatment strategies that target specific immunological pathways. a systematic literature review was conducted using pubmed, scopus, and web of science databases, focusing on peer-reviewed articles published between 2010 and 2024. search terms included graves' disease, hyperthyroidism, autoimmune thyroid, tsh receptor antibodies, immunomodulatory therapy, and thyroid autoimmunity. articles were screened for relevance and methodological quality. the pathophysiology involves complex molecular interactions between genetic predisposition (hla-dr3, ctla-4 polymorphisms), environmental triggers including iodine excess and stress, and immune system dysregulation. cd11c+ b cells have emerged as novel therapeutic targets, demonstrating strong correlation with serum trab levels and disease activity markers. current treatment modalities include antithyroid drugs (methimazole, propylthiouracil), radioiodine therapy, and surgical thyroidectomy. emerging therapeutic approaches focus on trab-targeting strategies, including novel tshr antagonists (k1-70) and precision medicine strategies that incorporate detailed immunophenotyping profiles. recent advances in understanding immune mechanisms have opened promising new therapeutic avenues. trab-targeted biologics and personalized precision medicine approaches show significant potential for individualized treatment strategies, potentially improving long-term remission rates and substantially reducing disease recurrence in comprehensive graves' disease management.